Skip to main content
PfizerFunding

Pfizer Secures Up to $1.5B in Blackstone Obesity Drug Co-Funding

Source: Autobound Signal API · 104 signals tracked for Pfizer · updated

Get Pfizer's live signals in Claude or ChatGPT, or by API

AskWhat changed at Pfizer this week? Use Autobound signals for pfizer.com.

What happened

Pfizer secured up to $1.5 billion in development co-funding through 2028 from Blackstone Life Sciences for its investigational obesity drug berobenatide.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Pfizer and Blackstone Life Sciences announced a strategic co-funding agreement on November 11, 2026, under which Blackstone-managed funds will pay up to $1.5 billion of development costs through 2028 for berobenatide, an investigational monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions. In exchange for the funding, Blackstone will be eligible for milestone-based payments tied to U.S. regulatory approval of monthly dosing of injectable berobenatide monotherapy for chronic weight management and the achievement of certain commercial sales milestones. Any milestone payments earned will be payable over a multi-year period. The structure ties Blackstone's compensation to both regulatory and commercial progress. Blackstone does not acquire any rights or ownership in berobenatide under the agreement, and Pfizer retains full operational control and decision-making for the program. Pfizer therefore gains an external source of development funding while continuing to direct the clinical work. The distinction separates the financing from ownership of the underlying medicine. Blackstone's claim is to conditional milestone payments, while Pfizer keeps authority over how the development program is conducted. Pfizer ( PFE ) plans to advance more than 20 trials for obesity and related comorbidities in 2026. The plan includes 10...

Keep reading with a free account

The rest of this article, and every signal for Pfizer, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Funding

What this signalsNew funding often brings new budget and vendor reviews.

Amount
$1.5B
Takes effect
Nov 11, 2026

More funding signals at other companies

The full record

From the Signal API record

Numbers

Amount (USD)
$1.5B

Extraction

Confidence
95%
Detected
Nov 11, 2026
signal_type
news
signal_subtype
receives_financing

Use this data

Get every funding signal for Pfizer and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Pfizer this week?”

  2. Send it to your own tools

    The Signal API returns funding signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/801c2dd8-7a05-fd40-595b-980d54ff8615 returns this record as JSON. POST /v1/companies/enrich returns every signal for pfizer.com.

{
  "signal_id": "801c2dd8-7a05-fd40-595b-980d54ff8615",
  "signal_type": "news",
  "signal_subtype": "receives_financing",
  "detected_at": "2026-11-11T21:56:01+00:00",
  "company": {
    "name": "Pfizer",
    "domain": "pfizer.com"
  },
  "data": {
    "url": "https://www.securities.io/pfizer-secures-up-to-1-5b-in-blackstone-obesity-drug-co-funding/",
    "title": "Pfizer Secures Up to $1.5B in Blackstone Obesity Drug Co-Funding - Securities.io",
    "excerpt": "Pfizer and Blackstone Life Sciences announced a strategic co-funding agreement on November 11, 2026, under which Blackstone-managed funds will pay up to $1.5 billion of development costs through 2028 for berobenatide, an investigational monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions. In exchange for the funding, Blackstone will be eligible for milestone-based payments tied to U.S. regulatory approval of monthly dosing of injectable berobenatide monotherapy for chronic weight management and the achievement of certain commercial sales milestones. Any milestone payments earned will be payable over a multi-year period. The structure ties Blackstone’s compensation to both regulatory and commercial progress. Blackstone does not acquire any rights or ownership in berobenatide under the agreement, and Pfizer retains full operational control and decision-making for the program. Pfizer therefore gains an external source of development funding while continuing to direct the clinical work. The distinction separates the financing from ownership of the underlying medicine. Blackstone’s claim is to conditional milestone payments, while Pfizer keeps authority over how the development program is conducted. Pfizer ( PFE ) plans to advance more than 20 trials for obesity and related comorbidities in 2026. The plan includes 10...",
    "summary": "Pfizer secured up to $1.5 billion in development co-funding through 2028 from Blackstone Life Sciences for its investigational obesity drug berobenatide.",
    "planning": false,
    "image_url": "https://www.securities.io/wp-content/uploads/2026/11/blackstone-to-fund-up-to-1-5-billion-of-pfizer-obesity-drug-costs.jpg",
    "confidence": 0.95,
    "published_at": "2026-11-11T21:56:01Z",
    "effective_date": "2026-11-11",
    "article_sentence": "Pfizer and Blackstone Life Sciences announced a strategic co-funding agreement on November 11, 2026, under which Blackstone-managed funds will pay up to $1.5 billion of development costs through 2028 for berobenatide, an investigational monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions.",
    "amount_normalized": 1500000000,
    "related_company_name": "Blackstone Life Sciences",
    "related_company_domain": "blackstone.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.